Show simple item record

dc.contributor.authorRobak, T
dc.contributor.authorMatutes, E
dc.contributor.authorCatovsky, D
dc.contributor.authorZinzani, PL
dc.contributor.authorBuske, C
dc.contributor.authorComm, ESMOG
dc.date.accessioned2018-07-20T15:33:57Z
dc.date.issued2015-09
dc.identifier5
dc.identifier.citationANNALS OF ONCOLOGY, 2015, 26 pp. V100 - V107
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2107
dc.identifier.eissn1569-8041
dc.identifier.doi10.1093/annonc/mdv200
dc.format.extentV100 - V107
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.titleHairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro)
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdv200
rioxxterms.licenseref.startdate2015-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfANNALS OF ONCOLOGY
pubs.notesaffiliation: Robak, T (Reprint Author), Med Univ Lodz, Dept Hematol, Lodz, Poland. Robak, T., Med Univ Lodz, Dept Hematol, Lodz, Poland. Matutes, E., Univ Barcelona, Hosp Clin, Haematopathol Unit, Barcelona, Spain. Catovsky, D., Inst Canc Res, Haematooncol Res Unit, Sutton, Surrey, England. Zinzani, P. L., Univ Bologna, Seragnoli Inst Hematol, Bologna, Italy. Buske, C., Univ Hosp, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany. keywords-plus: TERM-FOLLOW-UP; MUTATION-SPECIFIC ANTIBODY; MARGINAL ZONE LYMPHOMA; ALLOGENEIC TRANSPLANTATION; ABDOMINAL LYMPHADENOPATHY; CLADRIBINE TREATMENT; 2ND MALIGNANCIES; INTERFERON-ALPHA; CANCER INCIDENCE; RITUXIMAB research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] researcherid-numbers: Zinzani, Pier Luigi/J-9182-2016 orcid-numbers: Zinzani, Pier Luigi/0000-0002-2112-2651 funding-acknowledgement: Roche; Janssen; GlaxoSmithKline; Medimmune funding-text: TR has reported honoraria from Roche and research grants from Roche, Janssen, GlaxoSmithKline and Medimmune. PLZ has reported honoraria from Takeda Millennium, Roche, Celgene, Pfizer, Gilead and Sandoz. CB has reported honoraria from Roche, Pfizer, Celgene, Pharmacyclics and Janssen and research grants from Roche and Janssen. The other authors have reported no potential conflicts of interest. number-of-cited-references: 72 times-cited: 14 usage-count-last-180-days: 0 usage-count-since-2013: 10 journal-iso: Ann. Oncol. doc-delivery-number: CR5PD unique-id: ISI:000361394500009 oa: gold_or_bronze da: 2018-07-20
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume26
pubs.embargo.termsNot known
dc.contributor.icrauthorCatovsky, Danielen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record